Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 72.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,363 shares of the biotechnology company's stock after selling 47,305 shares during the period. Mutual of America Capital Management LLC's holdings in Arrowhead Pharmaceuticals were worth $234,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 297.6% during the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $49,000. KBC Group NV boosted its stake in shares of Arrowhead Pharmaceuticals by 40.8% during the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 2,132 shares in the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at about $137,000. Finally, Cerity Partners LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the first quarter valued at about $141,000. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Trading Down 3.2%

NASDAQ ARWR traded down $0.52 on Friday, hitting $15.74. The company's stock had a trading volume of 1,763,918 shares, compared to its average volume of 2,024,831. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $29.59. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.31. The company's 50-day simple moving average is $16.39 and its 200 day simple moving average is $16.23. The firm has a market cap of $2.17 billion, a P/E ratio of -11.24, a PEG ratio of 19.12 and a beta of 0.93.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating the consensus estimate of ($0.06) by $2.81. The business had revenue of $542.71 million for the quarter, compared to analysts' expectations of $116.27 million. During the same period in the previous year, the company earned ($1.02) EPS. Research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ARWR shares. Citigroup cut their price objective on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $43.71.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.